MiMedx Group Inc
NASDAQ:MDXG
Intrinsic Value
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. [ Read More ]
The intrinsic value of one MDXG stock under the Base Case scenario is 6.24 USD. Compared to the current market price of 6.29 USD, MiMedx Group Inc is Overvalued by 1%.
Valuation Backtest
MiMedx Group Inc
Run backtest to discover the historical profit from buying and selling MDXG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MiMedx Group Inc
Current Assets | 164.3m |
Cash & Short-Term Investments | 82m |
Receivables | 53.9m |
Other Current Assets | 28.4m |
Non-Current Assets | 74.8m |
PP&E | 9.1m |
Intangibles | 24.7m |
Other Non-Current Assets | 41m |
Current Liabilities | 46m |
Accounts Payable | 9m |
Accrued Liabilities | 33.2m |
Other Current Liabilities | 3.8m |
Non-Current Liabilities | 50.3m |
Long-Term Debt | 48.1m |
Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
MiMedx Group Inc
Revenue
|
321.5m
USD
|
Cost of Revenue
|
-54.6m
USD
|
Gross Profit
|
266.8m
USD
|
Operating Expenses
|
-224.6m
USD
|
Operating Income
|
42.3m
USD
|
Other Expenses
|
13.5m
USD
|
Net Income
|
55.8m
USD
|
Free Cash Flow Analysis
MiMedx Group Inc
What is Free Cash Flow?
MDXG Profitability Score
Profitability Due Diligence
MiMedx Group Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
MiMedx Group Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
MDXG Solvency Score
Solvency Due Diligence
MiMedx Group Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
MiMedx Group Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDXG Price Targets Summary
MiMedx Group Inc
According to Wall Street analysts, the average 1-year price target for MDXG is 12.75 USD with a low forecast of 11.11 USD and a high forecast of 14.7 USD.
Ownership
MDXG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MDXG Price
MiMedx Group Inc
Average Annual Return | 25.27% |
Standard Deviation of Annual Returns | 95.56% |
Max Drawdown | -83% |
Market Capitalization | 919.8m USD |
Shares Outstanding | 148 076 100 |
Percentage of Shares Shorted | 3.55% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.
Contact
IPO
Employees
Officers
The intrinsic value of one MDXG stock under the Base Case scenario is 6.24 USD.
Compared to the current market price of 6.29 USD, MiMedx Group Inc is Overvalued by 1%.